To validate this finding, we studied the combination of ispinesib with current standard of care drugs for FLT3-ITD+ AML, including broad-spectrum chemotherapeutic drugs (cytarabine), approved FLT3 inhibitors (midostaurin, gilteritinib and quizartinib) and the BCL2 family member blocker venetoclax. This evidence concerns the gene FLT3 and acute myeloid leukemia.